Azenta, INC 8-K filings

Azenta, Inc. announced the closing of the sale of its B Medical Systems business to Thelema S. r.l. for a fixed purchase price of $63 million.

Azenta, Inc. announced its second quarter fiscal year 2026 results, reporting revenue of $145 million, and revised its full-year guidance downwards due to a cautious demand environment and execution gaps.

Azenta, Inc. has appointed former Maravai LifeSciences CEO Trey Martin as President of its Multiomics business, succeeding Ginger Zhou.

Azenta, Inc. announced that the sale of B Medical Systems to Thelema has been delayed due to the buyer's failure to secure necessary financing.

Azenta, Inc. has acquired UK Biocentre Limited for GBP 20.5 million, establishing a new European hub for sample management and storage services.

Azenta, Inc. announced its first quarter fiscal 2026 financial results, reporting revenue consistent with expectations but facing gross margin challenges, while reaffirming its full-year guidance.

Azenta, Inc. announced that its stockholders approved all proposals at the annual meeting, including director elections, executive compensation, and an equity plan amendment.

Azenta, Inc. announced its subsidiary, Azenta Germany GmbH, has entered into a definitive agreement to sell its B Medical Systems business to THELEMA S. R.L. for $63 million, aiming to streamline its portfolio.

Azenta, Inc. has authorized a new stock repurchase program of up to $250 million, effective December 9, 2025, alongside an upcoming Investor Day.

Azenta, Inc. announced robust financial results for the fourth quarter and full fiscal year 2025, driven by Multiomics growth and significant Adjusted EBITDA margin expansion, with a positive outlook for fiscal 2026.

Azenta, Inc. reported flat revenue for the third fiscal quarter of 2025, but showed significant margin expansion and reiterated its full-year guidance, despite a non-cash impairment charge related to discontinued operations.

Azenta, Inc. announced the voluntary resignation of its Vice President and Chief Accounting Officer, Violetta Hughes, effective August 6, 2025, to pursue external opportunities, with no disagreements cited.

Azenta, Inc. announces the departure of Senior Vice President, General Counsel and Secretary Jason W. Joseph, effective May 15, 2025, and the appointment of Ephraim Starr as his successor.

Azenta, Inc. announced its second quarter fiscal 2025 results, reporting a 5% increase in revenue and an improved adjusted EBITDA margin.

Azenta, Inc. reports the departure of David Wang, President of Sample Management Solutions, effective April 9, 2025, with a consulting agreement in place until December 9, 2025.

Azenta, Inc. announced its first quarter fiscal 2025 results, showcasing a 4% year-over-year revenue increase and positive momentum in Sample Management Solutions and Multiomics services.

Azenta, Inc. is actively pursuing the sale of its B Medical Systems segment to streamline its portfolio and concentrate on its Sample Management Solutions and Multiomics businesses.

Azenta reports its fiscal year 2024 results, including a plan to sell B Medical Systems, and the appointment of Lawrence Y. Lin as the new CFO.

Azenta, Inc. has added three new independent directors to its board and established a Value Creation Committee to drive long-term shareholder value.

Azenta, Inc. has announced the appointment of John Marotta as its new President and CEO, effective September 9, 2024, succeeding Dr. Stephen Schwartz who is retiring.

Azenta, Inc. announced its financial results for the third quarter of fiscal year 2024, showing revenue growth and improved profitability.

Azenta, Inc. announces the retirement of CEO Stephen Schwartz after 14 years, initiating a search for his successor while ensuring a smooth transition.

Azenta's second quarter fiscal 2024 results show revenue growth but a significant GAAP loss, leading to lowered revenue guidance for the year, while raising earnings guidance.

Azenta, Inc. presented its strategic vision and financial targets at its Investor Day, emphasizing transformation for sustained profitable growth.

Azenta's first quarter fiscal 2024 results show a 13% year-over-year revenue decline, although the company exceeded expectations on both top and bottom lines.

Azenta, Inc. held its annual meeting on January 30, 2024, where stockholders elected directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor.

Azenta, Inc. has reorganized its business into three segments: Multiomics, Sample Management Solutions, and B Medical Systems, effective October 1, 2023, to enhance its commercial strategy and profitability.

Ellen M. Zane will not seek re-election to Azenta Inc.'s Board of Directors at the upcoming 2024 Annual Meeting, reducing the board size to nine members.